Paul Conyngham built a personalized cancer vaccine for his dog with help from ChatGPT

Summary

According to the report, Australian tech expert Paul Conyngham developed a personalized mRNA vaccine for Rosie, his dog, after conventional treatments failed to shrink her tumor. The story drew attention because it involved AI tools, including ChatGPT and Google DeepMind’s AlphaFold, in a process that combined planning, genetic analysis and treatment design.

Conyngham told Today that Rosie was his “best mate” and had been with him through difficult moments in life, which pushed him to do everything he could after her diagnosis. The article says he adopted Rosie, a Staffy-Shar Pei mix, in 2019, and that five years later she was diagnosed with cancer. Even after spending thousands on treatments such as chemotherapy, the tumor did not get smaller.

At that point, the report says, he decided to use AI to pursue another route. Conyngham, who has spent 17 years in machine learning and data analysis, told The Australian that he went to ChatGPT to come up with a plan for how to do it.

In practice

The process described in the story began with sequencing Rosie’s DNA to better understand the problem and look for a treatment path. For that step, Conyngham contacted the University of New South Wales Ramaciotti Centre for Genomics, which provided genomic sequencing for 3,000 Australian dollars.

He then compared Rosie’s healthy DNA with the tumor DNA to identify what had changed. In the explanation quoted by the article, he likened that step to comparing the original engine of a car with the same engine after 300,000 kilometers to see where the damage is.

Next, he used AlphaFold, described in the story as a Google DeepMind AI system that helps with understanding protein functions. According to the article, that allowed him to pinpoint mutations and connect them to the drugs needed to treat the tumor. From there, Conyngham and UNSW developed a tailored mRNA vaccine for Rosie. The piece adds that an mRNA vaccine triggers an immune response by using synthetic messenger RNA to direct cells to generate a harmless viral protein.

Rosie received her first injection in December and then booster shots followed. The article says the tumor has decreased notably after treatment, although the cancer was already at an advanced stage.

What we still don't know

The report itself remains cautious about how far the case can be taken. While it quotes UNSW RNA Institute director Pall Thordarson saying this is the first time a personalized cancer vaccine has been designed for a dog, the story does not provide detailed clinical data, response rates, durability information or evidence of formal scientific review of the full process.

The article also does not specify what type of cancer Rosie has, how large the tumor reduction was in exact terms, or what outcomes may come from the second vaccine Conyngham is now developing to target a residual tumor.

Even so, the piece presents the case as a sign of what time-sensitive personalized medicine might look like. Thordarson says, according to the report, that this remains at the frontier of cancer immunotherapeutics and that what Rosie is teaching could ultimately help humans as well.

Why it matters

• It shows a concrete use of AI tools such as ChatGPT and AlphaFold in a highly specific biomedical problem.

• It highlights personalized medicine built from comparing healthy DNA with tumor DNA.

• It points to possible relevance for human treatments, though the story does not present broad clinical evidence yet.

• It also underlines important limits: this is a single case, in advanced cancer, with several unanswered questions.